Located in Menlo Park, CA, Intersect ENT’s initial focus is chronic sinusitis, a condition that affects one out of eight adults in the U.S. and has a greater impact on quality of life than congestive heart failure or chronic back pain.For these chronic sinus sufferers, their condition deeply impacts their quality of life and often requires a complex combination of medical and surgical therapy. While surgical solutions relieve symptoms in many patients, disease can recur even in the postoperative period; the majority have symptoms that persist within the first year. We at Intersect ENT believed there had to be a better way — to improve both the patient experience and surgical outcomes as well as alleviate physician frustration with disease recurrence. We developed the PROPEL steroid-releasing implant with these goals in mind.
PROPEL sinus implants props open the sinus cavity following surgery and allows for localized delivery of steroid directly to the sinus mucosa, as it dissolves. For patients, this may mean less invasive treatment options, improved surgical outcomes, and reduced need for systemic drugs such as oral steroids which can lead to serious side effects.
Innovation and creativity are driving forces for our company. Intersect ENT holds more than 25 issued U.S. patents and more than 90 patents and pending applications worldwide.
Intersect ENT (NASDAQ: XENT) is a publicly traded company.
PROPEL sinus implants props open the sinus cavity following surgery and allows for localized delivery of steroid directly to the sinus mucosa, as it dissolves. For patients, this may mean less invasive treatment options, improved surgical outcomes, and reduced need for systemic drugs such as oral steroids which can lead to serious side effects.
Innovation and creativity are driving forces for our company. Intersect ENT holds more than 25 issued U.S. patents and more than 90 patents and pending applications worldwide.
Intersect ENT (NASDAQ: XENT) is a publicly traded company.
Location: United States, California, Menlo Park
Phone: +1 650-641-2100
Total raised: $60M
Founded date: 2003
Investors 3
| Date | Name | Website |
| - | US Venture... | usvp.com |
| - | Kleiner Pe... | kleinerper... |
| - | Norwest Ve... | nvp.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 25.02.2013 | Series D | $30M | US Venture... |
| 01.11.2010 | - | $30M | - |
Mentions in press and media 22
| Date | Title | Description |
| 20.09.2021 | Intersect ENT : Understanding the Difference between COVID-19 Symptoms and Sinus Disease World Sinus Health Awareness Day 2021 | September 20, 2021-Alexandria, Virginia-The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS), in partnership with Intersect ENT, Inc., launched a public education campaign that provides clinically-developed information by ... |
| 06.08.2021 | Intersect ENT : Medtronic to Acquire Intersect ENT | DUBLIN and MENLO PARK, Calif., Aug. 6, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has entered into a definitive agreement with Intersect ENT (NASDAQ: XENT), a global ear, ... |
| 22.07.2021 | Intersect ENT : Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan (Form 8-K) | Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan MENLO PARK, Calif. - July 22, 2021 - Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat ('ENT') medical technology le... |
| 14.07.2014 | Intersect ENT sets terms for $65M IPO | Intersect ENT said today that it hopes to raise as much as $65 million in an initial public offering of 5 million shares. Intersect, which makes drug-eluting devices designed to treat ear, nose & throat conditions, said it plans to pric... |
| 27.06.2014 | Intersect ENT hopes to raise $80 million in newly registered initial public offering | Medtech funding for the week of June 23, 2014 | Intersect ENT registers $80M IPO for sinus implants June 24, 2014 by Arezu Sarvestani Drug-eluting devices maker Intersect ENT hopes to raise as much as $80 million in a newly registered initial public offering, according to SEC documents f... |
| 24.06.2014 | Intersect ENT registers $80M IPO for sinus implants | Drug-eluting devices maker Intersect ENT hopes to raise as much as $80 million in a newly registered initial public offering, according to SEC documents filed this week. Intersect has yet to detail pricing or the number of shares it’ll offe... |
| 14.01.2014 | Medtronic-backed Intersect ENT finalizes enrollment for third chronic sinusitus solution | According to the company website, “the product releases mometasone furoate, an advanced steroid with anti-inflammatory properties, directly into the sinus lining, then dissolves. The implant has more radial strength than the PROPEL products... |
| 30.08.2013 | Value, VCs and international markets: One industry leader’s answers on where medtech fits in | How is value changing for the medtech industry in this time of healthcare reform? Broad sweeping healthcare reform including accountable care has led hospitals and physicians to struggle to find avenues to cut costs and improve efficiency, ... |
| 19.08.2013 | Three women who make me optimistic about the future of healthcare | It’s this combination that makes me optimistic about the future of healthcare. If people who are curious, determined and willing to help are focused on the problems of overtreatment, silos, and the lack of data, all those problems are doome... |
| 10.04.2013 | iRhythm raises $16M for patch that stores heartbeat data to help spot arrhythmia | When it’s time to take off the patch, patients send it to iRhythm’s national clinical center for processing. The data is assembled into reports that are made available to physicians, but patients also get access to them. The U.S. Food and D... |
Show more